

Notice of Expiry of Listed Options (ASX:NTIOA)

Neurotech International Limited (ASX: NTI) ("NTI" or "the Company"), advises that the attached letter has been sent to registered holders of the Company's listed options (ASX: NTIOA) ("Listed Options"), noting that the Listed Options which are exercisable at \$0.135 will expire at 5:00PM (WST) on 30 January 2025 ("Expiry Date").

Official quotation of the Listed Options on ASX will cease at close of trading on Thursday, 23 January 2025, being four business days before the Expiry Date.

Authority

This announcement has been authorised for release by the Company Secretary of Neurotech International Limited.

Investors:

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

16 December 2024

Dear Optionholder,

Notice of Expiry of Listed Options (ASX: NTIOA)

Neurotech International Limited (ASX: NTI) ("NTI" or "the Company"), gives notice of the upcoming expiry of listed NTIOA Options (\$0.135, 30 January 2025) ("Options") at 5:00pm WST on 30 January 2025 ("Expiry Date").

There is no obligation on Optionholders to exercise their Options. However, under paragraph 5.2 of Appendix 6A of the ASX Listing Rules, the Company is required to advise Optionholders of the information contained in this letter.

The courses of action available to Optionholders are as follows:

1) Sell your Options:

Please note that official quotation of the Options on ASX will cease at close of trading on Thursday, 23 January 2025, being 4 business days before the Expiry Date.

2) Do nothing and allow your Options to expire:

If you do not exercise or sell your Options in the manner described in this letter, they will expire at 5:00pm (WST) on the Expiry Date, being 30 January 2025, and your right to subscribe for fully paid ordinary shares in the capital of the Company (Shares) at \$0.135 per Share will lapse.

3) Exercise your Options:

If you wish to exercise your Options, you must complete the "Notice of Exercise of Options" (**Notice of Exercise**) form accompanying this letter and provide the completed Notice of Exercise together with payment of \$0.135 per Option being exercised in accordance with the instruction set out in the Notice of Exercise. Your completed Notice of Exercise and payment (in cleared funds) must be received by no later than 5:00pm (WST) on the Expiry Date, being 30 January 2025.

Technical information required by the ASX Listing Rules

In accordance with clause 5.2 of Appendix 6A of the ASX Listing Rules, the Company provides the following information:

- a) The name of the Optionholder, the number of Options held and the number of fully paid ordinary shares in Neurotech International Limited to be issued upon the conversion of the Options are set out in the personalised "Notice of Exercise of Option" form which has been mailed to all Optionholders at their registered address.
- b) Each NTIOA Option entitles the Optionholder to subscribe for one fully paid ordinary share in the capital of the Company upon payment of the exercise price of \$0.135 on or before the Expiry Date, being 30 January 2025.

- c) The market price of ordinary fully paid shares in NTI on the Australian Stock Exchange (ASX) was \$0.056 on 13 December 2024, being the last trading day in NTI prior to the date of this letter.
- d) The exercise price of these options is \$0.135 each.
- e) The due date for payment is 5:00pm WST on 30 January 2025.
- f) There is no obligation upon the holder to exercise their options, however, if payment is not received by the due date the options will lapse and all rights under the options will cease at that time.
- g) The options will cease to be quoted on ASX from close of trading on Thursday, 23 January 2025.
- h) During the three months preceding the date of this notice the highest market price of fully paid shares in NTI on ASX was A\$0.074 on 26 November 2024, and the lowest market price was A\$0.048 on 16 October 2024.
- i) The Board confirms that there is no underwriting agreement in place for the exercise of the Options.

The Company wishes to take this opportunity to thank you for your ongoing support. If you have any questions or require assistance in relation to this matter, please contact the Company Secretary on (08) 9389 3130 or via email at cosec@neurotechinternational.com.

Yours Sincerely,

Alessandra Gauvin
Company Secretary

E: cosec@neurotechinternational.com

T: +61 (8) 9389 3130